Jianzhijia Pharmaceutical Chain Group (605266) Fair Value & Analysis
Healthcare · CN · Market cap 2.6B CNY
Fair value as of: Jul 12, 2026
From 26 valuation models · updated 30 days ago
Fair value updated Jul 12, 2026, revised from ¥22.31 to ¥20.13 (−9.8%) since Jun 24, 2026. Share price +9.5% over the past month.
A solid business, screening 18% undervalued on our models.
What matters now
- Our model range runs from ¥15.10 (bear) to ¥25.16 (bull), base ¥20.13. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 51/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.
How to read this chart
60‑month range ¥14.86 – ¥61.52 · fair‑value band ¥15.10 – ¥25.16 · the ¥17.02 price screens below the ¥20.13 fair value. Dashed = 300-day average. As of Jul 12, 2026.
Analysis
Jianzhijia Pharmaceutical Chain Group (605266) currently trades at ¥17.02, while our model-based Fair Value estimate is ¥20.13, implying the stock looks roughly 18.3% undervalued today. The Quality Score stands at 51/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Jianzhijia Pharmaceutical Chain Group generated revenue of 8.7B CNY at a net margin of 1.7%. Revenue declined 8.9% year over year. It earns a return on equity of 5.5%. Net debt stands at 2.1B CNY. Fundamentals as of Jul 12, 2026
Our scenario range runs from ¥15.10 (bear case) to ¥25.16 (bull case); at ¥17.02, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 19% below its 52-week high and 4% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -15% fair-value upside, at 18%, 605266 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (¥91.83) versus Asset-Based (¥11.59). Highest evidence: Growth DCF (80).
Notify me when 605266 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 51 · Market factors (momentum, volatility) 42
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Jianzhijia Pharmaceutical Chain Group Co., Ltd. engages in the pharmaceutical retail business in China. The company offers pharmaceuticals, health foods, personal care products, household health products, convenience foods, and daily consumables through offline community professional pharmacies, convenience stores, community clinics, Chinese medicine …
Full company description
Jianzhijia Pharmaceutical Chain Group Co., Ltd. engages in the pharmaceutical retail business in China. The company offers pharmaceuticals, health foods, personal care products, household health products, convenience foods, and daily consumables through offline community professional pharmacies, convenience stores, community clinics, Chinese medicine clinics, and physical examination centers in both online and offline ways. The company was formerly known as Yunnan Jianzhijia Health-Chain Co., Ltd. and changed its name to Jianzhijia Pharmaceutical Chain Group Co., Ltd. in September 2022. Jianzhijia Pharmaceutical Chain Group Co., Ltd. was founded in 1998 and is based in Kunming, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Jianzhijia Pharmaceutical Chain Group reported revenue of ¥8.9B in FY2025 versus ¥5.2B in FY2021, a compound +14.3%/yr. Reported net income was ¥148M in FY2025, compounding −16.2%/yr from FY2021.
of which total revenue +20.6 pp · buybacks/dilution −4.5 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch 605266: get an alert when its fair value changes →
Peer Group
Pharmaceutical Retailers · 61 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc 6618 | HK$39.20 | HK$33.28 | -15% |
| Raia Drogasil S.A RADL3 | R$18.20 | R$15.58 | -14% |
| Yifeng Pharmacy Chain Co 603939 | ¥23.43 | ¥29.07 | +24% |
| DaShenLin Pharmaceutical Group 603233 | ¥18.23 | ¥23.86 | +31% |
| Corporativo Fragua, S.A. FRAGUAB | 463.00 MXN | 821.18 MXN | +77% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥12.74 | ¥10.57 | -17% |
| MedPlus Health Services Limited MEDPLUS | ₹690.20 | ₹379.25 | -45% |
| Yixintang Pharmaceutical Group 002727 | ¥11.46 | ¥9.45 | -18% |
| Anhui Huaren Health Pharmaceutical Co 301408 | ¥14.40 | ¥10.05 | -30% |
| Apotea AB APOTEA | kr 74.75 | kr 43.95 | -41% |
Compare Jianzhijia Pharmaceutical Chain Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Jianzhijia Pharmaceutical Chain Group (605266) overvalued or undervalued?
What is the fair value of 605266?
What is the quality score of 605266?
What is the revenue of Jianzhijia Pharmaceutical Chain Group (605266)?
What is the net profit margin of 605266?
Does Jianzhijia Pharmaceutical Chain Group pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Jianzhijia Pharmaceutical Chain Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.